4th Annual Cell Engager Therapeutics Summit 2022 | May 24-26 2022 | Boston, MA
Evvnt Promotion / evvnt
Archive
24.05.2022 - 26.05.2022 Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 09:00 - 15:00
Conference themes
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.
Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (TCEs), which are presently in Phase I and Phase II investigations since the Cell Engager Series began.
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.
Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (TCEs), which are presently in Phase I and Phase II investigations since the Cell Engager Series began.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Notes
Speakers: Antara Banerjee Associate Director, Immunology Research and Group Leader, Immuno Biologics Takeda Pharmaceutical Co. Ltd., Julie Bailis Director of Research Amgen Inc and more.
Speakers: Antara Banerjee Associate Director, Immunology Research and Group Leader, Immuno Biologics Takeda Pharmaceutical Co. Ltd., Julie Bailis Director of Research Amgen Inc and more.
Enquiries and Registration:
https://go.evvnt.com/1011482-1?pid=4832
Ms. Rosie Andre
General Medicine
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
